Drugmaker Humco Lands Warning Letter Over GMP Deficiencies, Unapproved Drugs

Drug Industry Daily
A A
The FDA delivered a warning letter to Humco for deviating from GMP standards and manufacturing unapproved and misbranded drugs.

To View This Article:

Login

Subscribe To Drug Industry Daily